Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cross-bridge Cycle01:26

Cross-bridge Cycle

As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Healthcare priorities and needs for LGBTQIA+ people with cystic fibrosis: A concept mapping study.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Apolipoprotein L1 Gene Genotype and Kidney Outcomes After Living Kidney Donation.

JAMA internal medicine·2026
Same author

The sociocultural environment and the mental health of sexual and gender minority parents.

Annals of epidemiology·2026
Same author

Associations of employment gain, employment loss and prolonged unemployment with depressive symptoms over time among sexual and gender minority adults in the USA: a retrospective cohort study.

BMJ public health·2026
Same author

Validation of the Brief Assessment of Stress and Eating (BASE) in transgender and gender-diverse adults.

Eating behaviors·2026
Same author

Pathways and Roadblocks: Navigating Family-Building for Sexual and Gender Minority People Assigned Male at Birth.

Perspectives on sexual and reproductive health·2026

関連する実験動画

Updated: Jul 4, 2026

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis
06:12

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis

Published on: January 11, 2014

脊髄筋縮症 脊髄筋縮症 脊髄筋縮症 脊髄筋縮症 脊髄筋縮症

Mitchell R Lunn1, Ching H Wang

  • 1Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

Lancet (London, England)
|June 24, 2008
PubMed
まとめ

脊髄筋縮 (SMA) は,モーターニューロンの喪失と筋肉の弱さを引き起こす遺伝疾患です. その分子基盤の理解における進歩は,新しい治療戦略と改善された患者ケアにつながりました.

科学分野:

  • 神経学 神経学とは
  • 遺伝学 遺伝学とは
  • 分子生物学は分子生物学である.

背景:

  • 脊髄筋縮 (SMA) は,自己相性後退性神経変性障害である.
  • モーターニューロンの変性,骨格筋縮,一般的な弱さによって特徴付けられます.
  • 生存モーターニューロン1 (SMN1) 遺伝子の同同胞性障害によって引き起こされる.

研究 の 目的:

  • 脊髄筋縮の総合的な見直しをするために.
  • 臨床的症状,分子病原性,診断戦略,治療開発を統合する.
  • 臨床試験の証拠や,医療基準の変化について議論する.

主な方法:

  • 文献レビューと既存の研究の合成.
  • 臨床的症状と分子病原性の分析.
  • 臨床試験データを含む,診断戦略と治療開発の評価.

主要な成果:

  • 分子病原性メカニズムの解明.
  • SMN1遺伝子領域を標的とした治療戦略の開発.
  • 開発の様々な段階における治療薬候補者の特定.

さらに関連する動画

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice

Published on: October 3, 2011

関連する実験動画

Last Updated: Jul 4, 2026

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis
06:12

Dissection of the Transversus Abdominis Muscle for Whole-mount Neuromuscular Junction Analysis

Published on: January 11, 2014

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice
05:55

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice

Published on: October 3, 2011

結論:

  • 医療技術の進歩は,SMA患者のケア基準を大幅に変更しました.
  • 進行中の研究は,診断方法と治療介入の精錬を継続しています.
  • SMAの包括的な理解は,効果的な患者管理に不可欠です.